Compare ARK Genomic Revolution ETF (ARKG) vs Dow Inc (DOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Dow Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.55, while Dow Inc trades at $30.53 (market cap $22.58B). The key difference: Dow Inc pays a 4.48% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Dow Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | DOW | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $44.55 | $41.87 |
52-Week Low | $24.02 | $20.65 |
Market Cap | — | $22.58B |
Enterprise Value | — | $38.27B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
DOW trades at $30.64, up 0.2% with a bullish technical signal and recent earnings beats. The company shows declining revenue trends from $56.9B in 2022 to $40.0B in 2025, with negative net income margins. Analyst consensus is mixed with 33% buy ratings and a $35.11 price target, representing 15% upside. Recent dividend payment of $0.35 provides income support amid challenging fundamentals.
While technical indicators suggest near-term strength, fundamental challenges persist with negative profitability and declining cash flow. The stock offers potential upside to analyst targets but faces execution risks in a competitive chemical sector. Dividend yield provides some cushion, but investors need sustained operational improvement for meaningful long-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
